2-Butan-2-yl-5-propan-2-ylthiophene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-Butan-2-yl-5-propan-2-ylthiophene
• 英文别名: 2-butan-2-yl-5-propan-2-ylthiophene
• 化学式: C₁₁H₁₈S
• 分子量: 182.33
• InChiKey: SMPXJZVXXWJTMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• SUBSTITUTED THIOPHENE OLIGOMERS AND POLYMERS
  申请人：Whitten David G.

  公开号：US20200245619A1

  公开（公告）日：2020-08-06

  The present disclosure provides an antimicrobial substrate including a substrate and a polythiophene polymer. The polythiophene polymer has a number of repeated monomer units from n is 5-14 or 30 to 120, a number average molecular weight (Mn) from 1,000 to 4,000 or 10,000 to 40,000; and a polydispersity index (PDI) from 1 to 1.3. The present disclosure also provides the polythiophene polymer and uses thereof.

  本公开提供了一种抗菌基底，包括一个基底和一个聚噻吩聚合物。该聚噻吩聚合物具有从n为5-14或30至120的重复单体单位数，数均分子量（Mn）从1,000至4,000或10,000至40,000，聚分散指数（PDI）从1至1.3。本公开还提供了该聚噻吩聚合物及其用途。
• JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
  申请人：Incyte Corporation

  公开号：US20170087158A1

  公开（公告）日：2017-03-30

  The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.

  本申请涉及Janus激酶（JAK）抑制剂，包括3-环戊基-3- [4-（7H-吡咯[2,3-d]嘧啶-4-基）-1H-吡唑-1-基]丙腈，用于治疗干眼症或改善干眼症的特定症状，如眼部不适，视觉障碍，泪膜不稳定，泪液高渗性和眼表炎症，以及相关的套件和组合物，包括局部组合物。
• Compound and liquid-crystal composition employing the same
  申请人：INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

  公开号：US10035956B2

  公开（公告）日：2018-07-31

  A compound and a liquid-crystal composition employing the same are provided. The compound has a structure represented by Formula (I) wherein Za and Zb are independently A1, A2, A3 and A4 are independently single bond, Z1, Z2, Z3, and Z4 are independently single bond, R is independently hydrogen, or C1-4 alkyl group; R1 and R2 are independently single bond, —O—(CH2)n—, —CH═CH—(CH2)2—, —(CH2)2—CH═CH—, —CH═CH—, or —C≡C—; n is an integer from 1 to 6; B1 and B2 are independently and, R3 is hydrogen, or methyl group.

  本研究提供了一种化合物和使用该化合物的液晶组合物。该化合物具有由式（I）表示的结构 其中 Za 和 Zb 分别独立为 A1、A2、A3 和 A4 都是独立的单键、 Z1、Z2、Z3 和 Z4 都是独立的单键、 R 独立地是氢、或 C1-4 烷基；R1 和 R2 独立地是单键、-O-(CH2)n-、-CH═CH-( )2-、-( )2-CH═CH-、-CH═CH- 或 -C≡C-；n 是 1-6 之间的整数；B1 和 B2 独立地是 R3为氢或甲基。
• Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
  申请人：Cayman Chemical Company, Inc.

  公开号：US10556862B2

  公开（公告）日：2020-02-11

  Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

  此处公开的是式 (I) 化合物 以及用式（I）化合物进行治疗的方法，其中 L1、L2、L4、R1、R4、R5、R6 和 s 如说明书中所定义。式（I）化合物是 EP4 激动剂，可用于治疗青光眼、神经性疼痛及相关疾病。
• Methods, systems, and compositions for promoting bone growth
  申请人：Cayman Chemical Company, Inc.

  公开号：US10729810B2

  公开（公告）日：2020-08-04

  The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

  本发明涉及用于向骨缺损部位局部输送治疗剂的新型骨组合物。治疗剂可促进骨缺损的修复和/或治疗疼痛、炎症、癌症和感染等疾病。组合物包括磷酸钙骨水泥和脱矿骨基质或胶原海绵。这些组合物可用于植入患者骨缺损部位。